Given that prostate tumor growth is driven by androgens and androgen receptors (AR), standard clinical treatment involves androgen deprivation therapy (ADT) combined with androgen receptor inhibitors, often supplemented with radiotherapy or chemotherapy [3]. This evidence concerns the gene AR and prostate neoplasm.